Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

B2M overexpression correlates with malignancy and immune signatures in human gliomas.

Scientific reports - 3 Mar 2021

Zhang Hao, Cui Biqi, Zhou Yulai, Wang Xinxing, Wu Wantao, Wang Zeyu, Dai Ziyu, Cheng Quan, Yang Kui

Abstract excerpt

Because of the limited treatment strategy of gliomas, the key of diagnosis and treatment is finding new molecular biomarkers. Here, we explored the potential of β2-microglobulin (B2M) to serve as a hopeful candidate for immunotherapy or diagnostic biomarker in gliomas. The genomic profiles, clinical characteristics, and immune signatures were analyzed based on TCGA and CGGA databases. We carried out the whole...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta 2-Microglobulin
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Immune Tolerance

Share to Immunotherapy

Share to Isocitrate Dehydrogenase

Share to PTEN Phosphohydrolase

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 33658560
DOI: 10.1038/s41598-021-84465-6
PMCID: PMC7930032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

B2M overexpression correlates with malignancy and immune signatures in human gliomas.PMID 33658560Read ↗

Impact of beta‐2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironmentSemantic proximity Read ↗

Systematic Identification of UBE2C As a Prognostic Biomarker and Correlated with Immunosuppression and Invasiveness in GliomaSemantic proximity Read ↗

Systematic Identification of UBE2C As a Prognostic Biomarker and Correlated with Immunosuppression and Invasiveness in GliomaSemantic proximity Read ↗

ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppressionSemantic proximity Read ↗

UBE2C is associated with Prognosis of Immunosuppression and Cell Invasiveness in GliomaSemantic proximity Read ↗

ANXA2 is Correlated With the Molecular Features and Clinical Prognosis of Glioma, and Acts as a Potential Marker of ImmunosuppressionSemantic proximity Read ↗

TMEM2 Combined with IDH and 1p19q in Refining Molecular Subtypes for Predicting Survival of Patients with Glioma.Semantic proximity Read ↗

[Advances of glioma biomarkers].Semantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.Semantic proximity Read ↗

PDIA3 correlates with clinical malignant features and immune signature in human gliomas.Semantic proximity Read ↗

BST2 is an immune-related prognostic biomarker for gliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.